Empowered Patient Podcast Precision Psychiatry Approach Using Neurotyping to Treat Depression with Dr. Kazu Okuda Universal Brain
Dr. Kazu Okuda, Founder, and CEO of Universal Brain, uses neurotyping based on EEG data to better understand the different types of depression and deliver more precise treatments. To facilitate the availability of EEG data, Universal Brain has developed a next-generation EEG headset that is affordable and comfortable. The headset allows for the collection of data that can be used to analyze neural profiles of patients and tailor treatments. This precision psychiatry approach is the future of depression treatment and for identifying early warning signs of depression in the younger population.
Kazu explains, "We are using the term neurotyping to solve that kind of problem. Neurotyping is a term we use at Universal Brain, and it's a groundbreaking process of grouping individuals based on brain function measures derived from the EEG data. We'll look at specific reactions of the brain to visual and audio stimuli, which are called event-related potentials, and we are leveraging that kind of brain biomarkers and neurotype the patient based on brain function."
"By examining the functioning of the cornea or systems from attention to memory and negative bias and reward function, we aim to reduce the heterogeneity of treatment groups using the brain function biomarkers because depression has a lot of phenotypes. There is no single depression, but we call it depressions because there are tons of variations of combination of the symptoms to meet the criteria of depression. So by neurotyping patients based on brain function, we reduce the heterogeneity of depressions and lead to better outcomes."
#UniversalBrain #Neurotyping #BrainBiomarkers #Depression #PrecisionPsychiatry